---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-073294"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:12:41.317530+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio reports Q4/FY2023 financials; first patient dosed with CABA-201 in myositis

## Summary
- Cash, cash equivalents and short-term investments $241.2M as of Dec 31, 2023, with runway into 1H26.
- R&D expenses $17.4M (Q4) and $55.4M (FY2023); G&A $5.7M (Q4) and $19.2M (FY2023).
- First patient dosed in Phase 1/2 RESET-Myositis trial; no CRS or ICANS observed in first 21 days.
- Initial clinical data from RESET-Myositis and RESET-SLE expected in 1H24; longer-term follow-up in 2H24.
- FDA granted Rare Pediatric Disease designation for CABA-201 in juvenile dermatomyositis.

## SEC filing metadata
- accession: 0001193125-24-073294
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/0001193125-24-073294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/d717290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-073294
- JSON: https://secwatch.observer/filing/0001193125-24-073294.json
- Plain text: https://secwatch.observer/filing/0001193125-24-073294.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: reported results
  source text: Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/0001193125-24-073294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.